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Purpose: To develop a statistical approach that compares patient selection strategies across clinical trials and
apply this approach to acute ischemic stroke clinical trials to identify the optimal inclusion criteria.
Methods: We developed a statistical approach that compares the number needed to treat to achieve one success
(NNT) along with the number needed to screen to achieve one success (NNS) and assesses if there are signiﬁcant
diﬀerences in inclusion criteria, treatment course, and clinical outcome among patients that may have been
included/excluded in the trials. We applied this approach to the study population from four recent positive acute
stroke clinical trials: MR CLEAN, EXTEND-IA, ESCAPE, and SWIFT PRIME, applying published trial criteria to an
independent registry of 612 acute stroke patients, since we did not have access to the complete trial data.
Results: Although reported NNT were similar for EXTEND-IA, SWIFT PRIME and ESCAPE, and somewhat higher
for MR CLEAN, NNS varied across the trials from 21 for EXTEND-IA, 27 for MR CLEAN, to 46 for ESCAPE and 64
for SWIFT PRIME, reﬂecting less and more stringent inclusion criteria, respectively. Although there were sig-
niﬁcant diﬀerences in imaging biomarkers and other clinical characteristics among patients that may have been
included/excluded in the trials, these diﬀerences did not translate to signiﬁcant diﬀerences in treatment course
or clinical outcomes.
Conclusions: Our study proposes a robust statistical approach that can be applied to a larger pooled trial dataset,
if made available, to objectively compare across clinical trials and inform inclusion criteria of future trials.
Pooled analysis of the acute stroke trial data is needed to determine which imaging biomarker inclusion criteria
are critical and which may be relaxed. If this procedure were applied across the pooled trial data, it could
decrease costs and reﬁne the design of future trials to be the most eﬃcacious for the greatest number of patients.
1. Introduction
Utilization of study population data is essential to clinical trial de-
sign. Optimizing inclusion criteria can not only decrease costs asso-
ciated with expensive screening strategies but it can also help ensure
trials are both eﬃcient and include patients who may beneﬁt from the
trial. With an increasing amount of trial data becoming available,
straightforward statistical approaches and methodologies are poised to
help clinical researchers best utilize existing trial data to inform the
design of upcoming trials. For example, there has been debate regarding
the use of advanced imaging biomarkers in recent positive acute stroke
clinical trials [1]. Screening for advanced imaging biomarkers is
expensive and it is critical that trials are designed to beneﬁt the greatest
number of patients.
Four recent clinical trials have demonstrated the value of en-
dovascular revascularization therapy in patients with acute ischemic
stroke up to 24 h since symptom onset, including MR CLEAN [2], ES-
CAPE [3], SWIFT PRIME [4], and EXTEND-IA [5]. In comparison with
the earlier trials which showed negative results [6], more patients
beneﬁtted from endovascular therapy with mechanical devices and the
average modiﬁed Rankin score improved, in varying degrees. The
major diﬀerence of these recent positive trials compared to the older
negative trials was the use of imaging biomarkers to select patients for
acute revascularization therapy. However, the positive trials diﬀer from
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each other in terms of the exact imaging biomarkers used for inclusion
criteria.
Noncontrast brain CT and CT angiography (CTA) were the primary
imaging biomarkers used in the aforementioned four clinical trials,
while perfusion-CT (PCT) and/or collateral imaging was employed in
EXTEND-IA and SWIFT PRIME to determine the infarct core and pe-
numbra. In these trials, only those patients with relative large mismatch
(> 1.2 penumbra mismatch or> 1.8 target mismatch, respectively)
were considered for enrollment. This strategy has resulted in concern
that these trials succeeded because of selection bias, “cherry-picking”
the patients that may have the best outcome while excluding others
who may also have beneﬁtted. It is critical to reﬁne the design of
clinical trials to be the most eﬃcacious for the greatest number of pa-
tients.
This study aims to develop a straightforward statistical approach
that can be used to identify optimal inclusion criteria and inform future
clinical trial design. We present an approach that estimates the number
needed to screen to achieve one success (NNS), using trial results and
inclusion criteria, which could be used to evaluate the feasibility of a
trial under consideration and assess inclusion criteria across trials. We
illustrate the statistical approach by comparing imaging biomarker-
based selection strategies across four acute stroke clinical trials.
2. Methods
2.1. Data
Ethics approval was obtained from our local Institutional Review
Board (IRB) and since this was a retrospective study, the IRB waived the
need for patient consent. Ideally, this study would utilize the pooled
trial data but since the complete trial data are unavailable, we com-
pared the inclusion criteria of imaging biomarkers across trials through
utilizing the published results and criteria from the MR CLEAN,
ESCAPE, SWIFT PRIME, and EXTEND-IA trials (Table 1) in combination
with an independent registry of stroke imaging data [1]. Published trial
results include the demographic and imaging biomarker inclusion cri-
teria, number of patients in the treated and control arms, proportion of
patients in each arm with a positive outcome, as well as number needed
to treat (NNT). The previously characterized independent registry [1]
includes baseline parenchymal, perfusion, and vascular imaging data of
612 acute ischemic stroke patients, as well as the time since symptom
onset, demographic information, treatment course, and clinical out-
comes of these patients. An interactive web application, available at
https://neuroradiology.shinyapps.io/strokeimbio/, can be used to ex-
plore this registry.
2.2. Statistical methods
From the published trial results, we extracted the absolute risk re-
duction (ARR) as the proportion of patients in the treatment arm with a
good outcome (mRS≤ 2) minus the proportion of patients in the con-
trol arm with a good outcome; the number needed to treat (NNT) is the
inverse of ARR.
For each trial, we used the published inclusion criteria to determine
which patients from the independent registry met the initial screening
criteria for possible enrollment based on age and time since symptom
onset (N). Of those patients who met the screening criteria, we identi-
ﬁed those that could have been included in each trial based on baseline
parenchymal, perfusion, and vascular imaging biomarkers (n). Next, for
each trial, we calculated the proportion (p= n/N) of those who met the
screening criteria that could have been included in the trial based on
the baseline imaging biomarkers. Using this proportion and the ARR,
the number needed to screen to achieve one success (NNS) is the inverse
of ARR times p, 1/(ARR*p).
To assess the uncertainty around these estimates, we used the
bootstrap method and sampled with replacement from the independent
registry 10,000 times. Complete statistical details and the algorithm can
be found in Supplemental Methods in the Online Supplement.
We compared the demographics, imaging biomarkers, treatment
course, and clinical outcome of patients across trials by considering
subgroups of patients that met the inclusion criteria of a trial but who
would have been excluded from another trial. For categorical outcomes,
we used Fisher's exact test and for continuous outcomes, we used the
nonparametric Wilcoxon rank sum test. Signiﬁcance was assessed at the
0.05 level. All statistical analyses were carried out in the R statistical
computing interface [7].
3. Results
From the published trial results, we tabulated the inclusion criteria
and calculated the absolute risk reduction (Table 1). Applying the
published inclusion criteria to the independent registry of 612 acute
ischemic stroke patients with<24 h since symptom onset, the fol-
lowing met the screening criteria for possible enrollment, based on age
and time since symptom onset: 445 (72.7%) for MR CLEAN and EX-
TEND-IA, 541 (88.4%) for ESCAPE, and 372 (60.2%) for SWIFT PRIME.
Of those who met the screening criteria, the following could have been
included in the trial based on imaging biomarkers: 120 for MR CLEAN
(27.0%), 72 (16.2%) for EXTEND-IA, 50 (9.2%) for ESCAPE, and 25
(6.7%) for SWIFT PRIME. We found that those who could have been
included in SWIFT PRIME were a subset of those who could have been
included in EXTEND-IA, and these were a subset of those patients who
could have been included in MR CLEAN (Fig. 1), illustrating the pro-
gression of stricter imaging inclusion criteria. While there was overlap
among those patients who met the inclusion criteria of ESCAPE and the
other three trials (Fig. 1), ESCAPE included some patients with longer
time since symptom onset that would have been excluded from all three
of the other trials.
Per the reported results in the literature, NNT was similar for
EXTEND-IA [5], SWIFT PRIME [4] and ESCAPE [3], and somewhat
higher for MR CLEAN [2] (Fig. 2A). NNS was more variable and re-
ﬂected the relative stringency of the inclusion criteria. NNS was 21 for
EXTEND-IA, 27 for MR-CLEAN, 46 for ESCAPE and 64 for SWIFT
PRIME (Fig. 2B).
As seen in Table 2, patients that could have been included in MR
CLEAN but excluded from EXTEND-IA (N=48), had lower median
ASPECT scores (7 compared to 8; p=0.006), larger median infarct
volumes (83.3 ml compared to 17.9 ml; p < 0.001), smaller median
penumbra volumes (43.8ml compared to 101.2 ml; p < 0.001) and
Table 1
Published inclusion criteria and trial results.
Inclusion criteria MR CLEAN ESCAPE SWIFT
PRIME
EXTEND-IA
Age (years) 18+ 18+ 18–80 18+
Time since symptom
onset (hours)
< 6 <12 <6 <6
Location ICA or M1
or M2 (A1&
A2)
ICA or M1 ICA or M1 ICA or M1 or
M2
Infarct volume any any < 50ml < 70ml
ASPECT any 6–10 6–10 any
Target mismatch any any > 1.8 any
Penumbra mismatch any any any > 1.2
Penumbra volume any any > 15ml > 10ml
Collateral any 2 or 3 any any
Trial results MR CLEAN ESCAPE SWIFT
PRIME
EXTEND-IA
Control (N) 267 150 98 35
Treated (N) 233 165 98 35
Absolute Risk
Reduction (ARR)
0.14 0.24 0.24 0.31
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thus, smaller median target mismatch (1.8 compared to 6.2;
p < 0.001).
SWIFT PRIME had the strictest inclusion criteria of the four trials,
resulting in only 25 of 445 (6.7%) registry patients eligible to be in-
cluded in the trial who met the screening criteria. Of the patients that
could have been included in MR CLEAN but excluded from SWIFT
PRIME (N=95), 61 of 95 (64.2%; p < 0.001) would have been ex-
cluded because of M2 involvement. Additionally, patients that would
have been excluded from SWIFT PRIME but who could have been in-
cluded in MR CLEAN had signiﬁcantly higher median age (73 compared
to 66; p=0.034), larger median infarct volumes (41.4ml compared to
15.8 ml; p=0.001), smaller median penumbra volumes (62.6 ml
compared to 118.5ml; p < 0.001), resulting in lower median target
mismatch (2.4 compared to 7.1; p < 0.001).
ESCAPE was not quite as strict as SWIFT PRIME in its inclusion
criteria but diﬀered from other trials by including patients up to 12 h
since symptom onset while excluding patients with less than two col-
laterals (Table 1). Not surprisingly, of patients that could have been
included in MR CLEAN but excluded from ESCAPE, 47 of 83 (56.6%;
p < 0.001) were excluded due to having less than two collaterals and
61 of 83 (73.5%; p < 0.001) were excluded due to M2 involvement.
Additionally, patients that would have been excluded from ESCAPE but
who could have been included in MRCLEAN had larger median infarct
volume (38.0ml compared to 18.4 ml; p=0.002), smaller median pe-
numbra volume (57.4ml compared to 102.3ml; p=0.001), resulting
in smaller median target mismatch (2.4 compared to 6.1; p < 0.001).
These diﬀerences among patients from the independent registry that
could have been included/excluded from the trials did not translate to
statistically signiﬁcant diﬀerences in treatment course or clinical out-
come in these patient subgroups (Table 2). For instance, the treatment
eﬀect of endovascular therapy and clinical outcomes in stroke patients
who were MR CLEAN candidates but not EXTEND-IA candidates was
not signiﬁcantly diﬀerent from the treatment eﬀect of endovascular
therapy and clinical outcomes in stroke patients who were MR CLEAN
candidates and EXTEND-IA candidates.
4. Discussion
Despite having a smaller number needed to treat to achieve one
success (NNT), acute stroke trials involving advanced imaging (for in-
stance, EXTEND-IA) resulted in a similar number needed to screen to
achieve one success (NNS) as those for acute stroke trials involving
conventional imaging (for instance, MR CLEAN). This ﬁnding indicates
that advanced imaging inclusion criteria result in a more pronounced,
and stricter, selection of the screened population. Patients meeting
imaging inclusion criteria for acute stroke trials involving advanced
imaging were subsets of patients meeting imaging inclusion criteria for
acute stroke trials involving conventional imaging.
Ideally, this approach would be applied to the pooled complete trial
data, providing the opportunity for a robust assessment and identiﬁ-
cation of the optimal inclusion criteria. Since these data were un-
available, we illustrated the approach using an independent registry.
We tried to determine whether diﬀerent outcomes following re-
vascularization therapy were observed in the patients meeting imaging
inclusion criteria for acute stroke trials involving conventional imaging
but not for acute stroke trials involving advanced imaging, but we did
not ﬁnd any statistically signiﬁcant diﬀerences in treatment course or
clinical outcome. However, the sample size of the independent registry
is limited, and we lacked suﬃcient power to detect small diﬀerences.
Further and most importantly, the patients included in the independent
registry were not treated based on the inclusion criteria of the diﬀerent
trials, which limits the interpretation that can be made of the outcomes
Fig. 1. Number of patients in the independent registry that could have been
included in the trials based on published inclusion criteria.
Fig. 2. (A) Number needed to treat to achieve one success (NNT) and (B) Number needed to screen to achieve one success. Bars represent 95% bootstrap conﬁdence
intervals around the estimates.
R.L. Ball, et al. Contemporary Clinical Trials Communications 14 (2019) 100355
3
in the diﬀerent subgroups of this registry. However, if this methodology
were applied to the pooled complete trial data and signiﬁcant diﬀer-
ences were found among imaging criteria and their relation to clinical
outcomes, inclusion criteria for future trials could be optimized, al-
lowing for more prescriptive criteria for imaging biomarkers that are
signiﬁcantly associated with clinical outcomes and less strict, more
inclusive criteria, for those imaging biomarkers that are not sig-
niﬁcantly associated with clinical outcomes.
Despite these limitations, our study should be seen as a robust sta-
tistical approach that can be applied to a larger pooled trial dataset, if
made available, to objectively compare across clinical trials and inform
inclusion criteria of future trials and decrease the high costs associated
with these trials. Pooled analysis of the acute stroke trial data is needed
to compare clinical outcomes between subgroups and to determine
which imaging biomarker inclusion criteria are critical and which may
be relaxed. If this procedure were applied across the pooled trial data, it
could reﬁne the design of future trials to be the most eﬃcacious for the
greatest number of patients.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.conctc.2019.100355.
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Table 2
Comparison of patients in the registry that could have been included in MRCLEAN but excluded from another trial versus those that could have been included in
either MRCLEAN or another trial. For example, columns 2 and 3 refer to patients in the registry that could have been included in MRCLEAN but excluded from
EXTEND-IA (n=48) versus those that could have been included in either MRCLEAN or EXTEND-IA (n= 72); see Fig. 1. Continuous characteristics summarized with
median [IQR] and categorical Characteristics summarized with N (%). For categorical outcomes, we used Fisher's exact test and for continuous outcomes, we used the
nonparametric Wilcoxon rank sum test. Signiﬁcant p-values in bold.
Imaging Biomarkers EXTEND-IA MRCLEAN p-value SWIFT PRIME MRCLEAN p-value ESCAPE MRCLEAN p-value
Number compared 72 48 25 95 50 83
Time since symptom onset
(in hours)
2.5 [1.8, 3.0] 2.5 [1.5, 3.0] 0.244 2.5 [2.0, 3.0] 2.5 [1.5, 3.0] 0.309 3.0 [2.0, 5.8] 2.5 [1.6, 3.0] 0.003
ASPECT 8.0 [7.0, 10.0] 7.0 [6.0, 9.0] 0.006 8.0 [8.0, 9.0] 8.0 [6.5, 10.0] 0.318 8.0 [8.0, 9.0] 8.0 [6.5, 10.0] 0.096
Infarct volume (in ml) 17.9 [7.5, 32.5] 83.3 [49.2,
107.0]
<0.001 15.8 [7.3,
30.7]
41.4 [15.1, 83.3] 0.001 18.4 [6.5,
38.1]
38.0 [16.8, 80.3] 0.002
Penumbra volumes (in ml) 101.2 [57.1,
123.6]
43.8 [23.5,
81.4]
<0.001 118.5 [100.7,
152.8]
62.6 [34.0,
102.9]<
<0.001 102.3 [69.6,
134.0]
57.4 [34.0,
105.2]<
0.001
Target mismatch (P+I)/I 6.2 [3.7, 10.6] 1.8 [1.4, 2.0] <0.001 7.1 [4.2, 18.4] 2.4 [1.8, 5.0] <0.001 6.1 [3.0, 17.9] 2.4 [1.8, 5.0] <0.001
Age (in years) 68.5 [59.0,
80.0]
73.0 [59.8,
78.3]
0.841 66.0 [57.0,
73.0]
73.0 [60.0, 80.5] 0.034 72.5 [56.0,
79.0]
67.0 [59.0,
78.5]<
0.726
Collateral (%) 0.086 0.133 <0.001
0 4 (5.6) 2 (4.2) 0 (0.0) 6 (6.3) 0 (0.0) 6 (7.2)
1 17 (23.6) 22 (45.8) 5 (20.0) 34 (35.8) 0 (0.0) 39 (47.0)
2 32 (44.4) 16 (33.3) 11 (44.0) 37 (38.9) 25 (50.0) 27 (32.5)
3 19 (26.4) 8 (16.7) 9 (36.0) 18 (18.9) 25 (50.0) 11 (13.3)
ICA (%) 11 (15.3) 2 (4.2) 0.073 7 (28.0) 6 (6.3) 0.006 15 (30.0) 3 (3.6) <0.001
M1 (%) 28 (38.9) 18 (37.5) 1 18 (72.0) 28 (29.5) <0.001 35 (70.0) 19 (22.9) <0.001
M2 (%) 33 (45.8) 28 (58.3) 0.197 0 (0.0) 61 (64.2) <0.001 0 (0.0) 61 (73.5) 0.001
Treatment course and clinical
outcome
EXTEND-IA MRCLEAN p-value SWIFT PRIME MRCLEAN p-value ESCAPE MRCLEAN p-value
Number treated (%) 49 (68.1) 38 (79.2) 0.214 19 (76.0) 68 (71.6) 0.803 30 (60.0) 59 (71.1) 0.254
Treatmenta for those treated
(%)
0.764 1 0.514
IV 47 (95.9) 36 (94.7) 19 (100.0) 64 (94.1) 28 (93.3) 57 (96.6)
IA 1 (2.0) 2 (5.3) 0 (0.0) 3 (4.4) 2 (6.7) 1 (1.7)
IV and IA 1 (2.0) 0 (0.0) 0 (0.0) 1 (1.5) 0 (0.0) 1 (1.7)
Recanalization (%) 41 (83.7) 26 (68.4) 0.125 16 (84.2) 51 (75.0) 0.543 27 (90.0) 42 (71.2) 0.06
mRS≤ 2 (%) 22 (44.9) 21 (55.3) 0.391 11 (57.9) 32 (47.1) 0.446 15 (50.0) 30 (50.8) 1
mRS (%) 0.774 0.75 0.631
0 7 (14.3) 3 (7.9) 4 (21.1) 6 (8.8) 3 (10.0) 7 (11.9)
1 8 (16.3) 11 (28.9) 3 (15.8) 16 (23.5) 5 (16.7) 14 (23.7)
2 7 (14.3) 7 (18.4) 4 (21.1) 10 (14.7) 7 (23.3) 9 (15.3)
3 10 (20.4) 4 (10.5) 3 (15.8) 11 (16.2) 6 (20.0) 8 (13.6)
4 7 (14.3) 5 (13.2) 3 (15.8) 9 (13.2) 2 (6.7) 10 (16.9)
5 1 (2.0) 1 (2.6) 0 (0.0) 2 (2.9) 0 (0.0) 2 (3.4)
6 6 (12.2) 4 (10.5) 1 (5.3) 9 (13.2) 4 (13.3) 6 (10.2)
missing 3 (6.1) 3 (7.9) 1 (5.3) 5 (7.4) 3 (10.0) 3 (5.1)
a IV= intravenous drug, IA= intraarterial, endovascular drug/technique.
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